MOORESTOWN, N.J., March 25, 2021 /PRNewswire/ -- Tabula Rasa
HealthCare, Incâ (TRHC) (NASDAQ:
TRHC), a healthcare technology company advancing safe use
of medications, has partnered with Infectious Disease (ID) Connect,
a leader in infectious diseases telemedicine and antimicrobial
stewardship. ID Connect will integrate TRHC's precision dosing
solution, DoseMeRxä, into its real-time decision support software
ILÚM Insightâ.
A solution that incorporates telemedical support, clinical
expertise and medication dose optimization
The integration of DoseMeRx with ILÚM Insight will provide ID
Connect customers with instant access to personalized dosing for
vancomycin and other antimicrobials, optimizing pharmacy workflow
and improving patient safety.
"Partnering with DoseMeRx, a leader in precision dosing, will
bring this important capability to our customers in a seamless
fashion, while further enhancing our already differentiated
Antimicrobial Stewardship solution," said Dave Zynn, president of ID Connect. "Together,
we will take patient care to a new level and create tremendous
efficiencies for practitioners."
ID Connect's ILÚM Insight platform provides physicians and
pharmacists real-time antimicrobial usage and resistance data to
help them select appropriate therapy, while managing costs,
toxicity and the potential for further resistance and transmission
of infection. Integrating DoseMeRx will enable ID Connect customers
to easily individualize the dosing of antimicrobials including
vancomycin – one of the most commonly used antibiotics in hospitals
today.
"TRHC is dedicated to improving health through innovative
technologies and service models, and ID Connect's mission is
aligned with ours," said TRHC Chairman and CEO Calvin H. Knowlton, PhD. "By bringing together
our technologies, we support physicians and pharmacists to improve
patient outcomes, individualize medication dosing and reduce the
workload for clinicians in healthcare organizations across the
country."
According to TRHC Executive Vice President for DoseMeRx,
Charles Cornish, the opportunity to
integrate DoseMeRx with Infectious Disease Connect's solution is of
benefit to customers looking for a closed-loop telemedicine
solution to clinical surveillance and dose optimization. "We are
glad to be part of a solution that incorporates telemedical
support, clinical expertise and dose optimization all in one
convenient solution," stated Cornish.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare (NASDAQ: TRHC) provides medication safety
solutions that empower healthcare professionals to optimize
medication regimens and reduce medication-related risk,
specifically targeting adverse drug events. TRHC's technology
solutions, including DoseMeRx™ and
MedWise™, improve patient outcomes, reduce
hospitalizations, and lower healthcare costs. TRHC's extensive
clinical tele-pharmacy network improves care for patients
nationwide. Its solutions are trusted by health plans and
pharmacies to help drive value-based payment results. For more
information, visit TRHC.com.
About DoseMeRx™
DoseMeRx is a TRHC
solution. It is the first precision dosing software developed
specifically for clinical practice. The DoseMeRx clinical decision
support platform empowers healthcare providers to optimize dosing
of high-risk parenteral medications to streamline operations,
reduce adverse drugs events, decrease costs and improve patient
outcomes. For more information on DoseMeRx, visit doseme-rx.com
About Infectious Disease Connect
Spun out of leading
academic medical center UPMC, ID Connect is a world leader in
telemedicine-enabled care of infectious diseases, antimicrobial
stewardship, and infection control and prevention. Our technology,
precision medicine, and data science are paired with world-class ID
physicians to effectively manage infectious diseases across the
U.S. At ID Connect, we strive to make people healthy, improve
outcomes, and keep our communities free of infectious diseases. For
more information, go to idctelemed.com.
Forward-Looking Statements
This press release includes forward-looking statements that we
believe to be reasonable as of today's date, including statements
regarding Medication Risk Mitigation technology. Such
statements are identified by use of the words "anticipates,"
"believes," "estimates," "expects," "intends," "plans," "predicts,"
"projects," "should," and similar expressions. These
forward-looking statements are based on management's expectations
and assumptions as of the date of this press release. Actual
results might differ materially from those explicit or implicit in
the forward-looking statements. Important factors that could cause
actual results to differ materially include: the need to innovate
and provide useful products and services; risks related to changing
healthcare and other applicable regulations; increasing
consolidation in the healthcare industry; managing our growth
effectively; our ability to adequately protect our intellectual
property; and the other risk factors set forth from time to time in
our filings with the SEC, including those factors discussed
under the caption "Risk Factors" in our most recent annual report
on Form 10-K, filed with the SEC on February
26, 2021, and in subsequent reports filed with or furnished
to the SEC, copies of which are available free of charge within the
Investor Relations section of the TRHC website http://ir.trhc.com
or upon request from our Investor Relations Department. Any
forward-looking statement speaks only as of the date on which it
was made. TRHC assumes no obligation and does not intend to update
these forward-looking statements, except as required by law, to
reflect events or circumstances occurring after today's date.
View original
content:http://www.prnewswire.com/news-releases/infectious-disease-connecta-announces-precision-dosing-powered-by-tabula-rasa-healthcares-dosemerxa-301255571.html
SOURCE Tabula Rasa HealthCare, Inc.